Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
42
SRPT Quote, Financials, Valuation and Earnings
Last price:
$122.64
Seasonality move
:
9.24%
Day range:
$120.00 - $122.18
52-week range:
$91.34 - $173.25
Dividend yield:
0%
P/E ratio:
79.16x
P/S ratio:
7.48x
P/B ratio:
9.54x
Volume:
204.8K
Avg. volume:
1.1M
1-year change:
28.94%
Market cap:
$11.6B
Revenue:
$1.2B
EPS (TTM):
$1.54
Analysts' Opinion
-
Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $185.10, Sarepta Therapeutics has an estimated upside of 51.85% from its current price of $121.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 100% downside risk from its current price of $121.90.
Fair Value
-
According to the consensus of 13 analysts, Sarepta Therapeutics has 51.85% upside to fair value with a price target of $185.10 per share.
SRPT vs. S&P 500
-
Over the past 5 trading days, Sarepta Therapeutics has underperformed the S&P 500 by -5.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sarepta Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sarepta Therapeutics has grown year-over-year revenues for 28 quarters straight. In the most recent quarter Sarepta Therapeutics reported revenues of $467.2M.
Earnings Growth
-
Sarepta Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sarepta Therapeutics reported earnings per share of $0.34.
Enterprise value:
11.7B
EV / Invested capital:
4.77x
Price / LTM sales:
7.48x
EV / EBIT:
78.58x
EV / Revenue:
7.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-24.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
62.36x
Gross Profit (TTM):
$1.4B
Return On Assets:
3.67%
Net Income Margin (TTM):
7.43%
Return On Equity:
12.48%
Return On Invested Capital:
5.51%
Operating Margin:
4.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $876M | $1.1B | $1.6B | $331.8M | $467.2M | |
| Gross Profit | $735.1M | $968M | $1.4B | $294.8M | $375.5M | |
| Operating Income | -$535.2M | -$399.3M | $81M | -$20.8M | $22.2M | |
| EBITDA | -$606.5M | -$594.7M | $187.2M | -$17M | $48.7M | |
| Diluted EPS | -$8.22 | -$7.83 | $1.54 | -$0.46 | $0.34 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $2.2B | $2.6B | $2.5B | $2.7B | |
| Total Assets | $2.8B | $2.7B | $3.2B | $3.1B | $3.6B | |
| Current Liabilities | $378.4M | $373.4M | $602.9M | $450.7M | $699.5M | |
| Total Liabilities | $1.9B | $2.2B | $2.7B | $2.3B | $2.4B | |
| Total Equity | $892M | $469.5M | $430.8M | $764.4M | $1.2B | |
| Total Debt | $700.5M | $1.1B | $1.5B | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$262.3M | -$538.7M | -$352.5M | -$114.7M | -$70.7M | |
| Cash From Investing | -$1.1B | -$91.6M | -$72.9M | -$210.6M | -$128.8M | |
| Cash From Financing | $771M | $133.8M | $77.8M | $15.4M | $13.8M | |
| Free Cash Flow | -$290.9M | -$615.2M | -$480.4M | -$155.5M | -$108M | |
SRPT
Sector
Market Cap
$11.6B
$46.1M
Price % of 52-Week High
70.36%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
28.94%
-30.52%
Beta (5-Year)
0.767
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$122.19
200-day SMA
Sell
Level
$129.63
Bollinger Bands (100)
Sell
Level
118.21 - 135.05
Chaikin Money Flow
Sell
Level
-56.6M
20-day SMA
Sell
Level
$125.99
Relative Strength Index (RSI14)
Sell
Level
48.37
ADX Line
Sell
Level
20.88
Williams %R
Neutral
Level
-67.6249
50-day SMA
Sell
Level
$122.90
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
410.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9332)
Sell
CA Score
(Annual)
Level (-2.4173)
Sell
Beneish M-Score
(Annual)
Level (-1.7247)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.7171)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Stock Forecast FAQ
In the current month, SRPT has received 12 Buy ratings 0 Hold ratings, and 1 Sell ratings. The SRPT average analyst price target in the past 3 months is $185.10.
-
Where Will Sarepta Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sarepta Therapeutics share price will rise to $185.10 per share over the next 12 months.
-
What Do Analysts Say About Sarepta Therapeutics?
Analysts are divided on their view about Sarepta Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sarepta Therapeutics is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Sarepta Therapeutics's Price Target?
The price target for Sarepta Therapeutics over the next 1-year time period is forecast to be $185.10 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SRPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sarepta Therapeutics is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SRPT?
You can purchase shares of Sarepta Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sarepta Therapeutics shares.
-
What Is The Sarepta Therapeutics Share Price Today?
Sarepta Therapeutics was last trading at $122.64 per share. This represents the most recent stock quote for Sarepta Therapeutics. Yesterday, Sarepta Therapeutics closed at $121.90 per share.
-
How To Buy Sarepta Therapeutics Stock Online?
In order to purchase Sarepta Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 2.54% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.94% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 1.16% over the past day.
